Lonhala Magnair Kit Patent Expiration

Lonhala Magnair Kit is a drug owned by Sumitomo Pharma America Inc. It is protected by 14 US drug patents filed from 2018 to 2022. Out of these, 10 drug patents are active and 4 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Dec 07, 2036. Details of Lonhala Magnair Kit's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10744277 Aerosol delivery device and method of operating the aerosol delivery device
Dec, 2036

(12 years from now)

Active
US10688518 Method of manufacturing a vibratable head for an aerosol generator and vibratable head for an aerosol generator
Nov, 2036

(11 years from now)

Active
US10376661 Opening element for opening an ampoule in an aerosol generation device and aerosol generation device comprising the opening element
Sep, 2035

(10 years from now)

Active
US9604018 Aerosol therapy device
May, 2033

(8 years from now)

Active
US9168556 Membrane nebulizer and method for welding a membrane to a carrier during the production of a membrane nebulizer
Sep, 2032

(7 years from now)

Active
US9789270 Inhalation therapy device comprising an ampoule for storing a medicament to be nebulized
Oct, 2030

(5 years from now)

Active
US10940110 Method and system for the treatment of chronic COPD with nebulized anticholinergic administrations
Feb, 2029

(4 years from now)

Active
US9265900 Disposable ampoule for an aerosol generating device
Dec, 2028

(4 years from now)

Active
US11278683 Inhalation therapy device comprising an ampoule for storing a medicament to be nebulized
Aug, 2026

(1 year, 8 months from now)

Active
US7931212 Fluid droplet production apparatus and method
Nov, 2025

(11 months from now)

Active
US7458372 Inhalation therapy device
Nov, 2024

(16 days ago)

Expired
US8511581 Fluid droplet production apparatus and method
Nov, 2023

(1 year, 27 days ago)

Expired
US7316067 Forming a perforate membrane by laser drilling and a subsequent electro-polishing step
Sep, 2022

(2 years ago)

Expired
US6962151 Inhalation nebulizer
Oct, 2020

(4 years ago)

Expired


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Lonhala Magnair Kit's patents.

Given below is the list of recent legal activities going on the following patents of Lonhala Magnair Kit.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 4th Year, Large Entity 05 Feb, 2024 US10744277
Payment of Maintenance Fee, 4th Year, Large Entity 20 Dec, 2023 US10688518
Payment of Maintenance Fee, 8th Year, Large Entity 12 Apr, 2023 US9168556
Payment of Maintenance Fee, 4th Year, Large Entity 06 Feb, 2023 US10376661
Payment of Maintenance Fee, 12th Year, Large Entity 17 Oct, 2022 US7931212
Recordation of Patent Grant Mailed 22 Mar, 2022 US11278683
Patent Issue Date Used in PTA Calculation 22 Mar, 2022 US11278683
Email Notification 03 Mar, 2022 US11278683
Issue Notification Mailed 02 Mar, 2022 US11278683
Application Is Considered Ready for Issue 16 Feb, 2022 US11278683


FDA has granted several exclusivities to Lonhala Magnair Kit. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Lonhala Magnair Kit, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Lonhala Magnair Kit.

Exclusivity Information

Lonhala Magnair Kit holds 1 exclusivities. All of its exclusivities have expired in 2020. Details of Lonhala Magnair Kit's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Dec 05, 2020

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Several oppositions have been filed on Lonhala Magnair Kit's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Lonhala Magnair Kit's generic, the next section provides detailed information on ongoing and past EP oppositions related to Lonhala Magnair Kit patents.

Lonhala Magnair Kit's Oppositions Filed in EPO

Lonhala Magnair Kit has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Feb 12, 2021, by Vectura Limited. This opposition was filed on patent number EP14815314A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP14815314A Feb, 2021 Vectura Limited Opposition rejected


US patents provide insights into the exclusivity only within the United States, but Lonhala Magnair Kit is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Lonhala Magnair Kit's family patents as well as insights into ongoing legal events on those patents.

Lonhala Magnair Kit's Family Patents

Lonhala Magnair Kit has patent protection in a total of 15 countries. It's US patent count contributes only to 23.7% of its total global patent coverage. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Lonhala Magnair Kit.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Lonhala Magnair Kit's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Dec 07, 2036 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Lonhala Magnair Kit Generic API suppliers:

Glycopyrrolate is the generic name for the brand Lonhala Magnair Kit. 44 different companies have already filed for the generic of Lonhala Magnair Kit, with Watson Labs having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Lonhala Magnair Kit's generic

Alternative Brands for Lonhala Magnair Kit

Lonhala Magnair Kit which is used for managing chronic obstructive pulmonary disease (COPD) through maintenance treatment of airflow obstruction., has several other brand drugs in the same treatment category and using the same active ingredient (Glycopyrrolate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name Treatment Area
Novartis
Seebri

(uses Glycopyrrolate)

Used for managing long-term airflow obstruction in patients with Chronic Obstructive Pulmonary Disease (COPD).
Utibron

(uses Glycopyrrolate)

Used for managing airflow obstruction in patients with COPD.

Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Glycopyrrolate. Given below is the list of those drugs and companies owning them.

Drug Owner Drug Name
Astrazeneca
Bevespi Aerosphere
Astrazeneca Ab
Breztri Aerosphere
Azurity
Prevduo
Casper Pharma Llc
Robinul
Robinul Forte
Merz Pharms
Cuvposa


Apart from brand drugs containing the same ingredient, some generics have also been filed for Glycopyrrolate, Lonhala Magnair Kit's active ingredient. Check the complete list of approved generic manufacturers for Lonhala Magnair Kit





About Lonhala Magnair Kit

Lonhala Magnair Kit is a drug owned by Sumitomo Pharma America Inc. It is used for managing chronic obstructive pulmonary disease (COPD) through maintenance treatment of airflow obstruction. Lonhala Magnair Kit uses Glycopyrrolate as an active ingredient. Lonhala Magnair Kit was launched by Sumitomo Pharma Am in 2017.

Approval Date:

Lonhala Magnair Kit was approved by FDA for market use on 05 December, 2017.

Active Ingredient:

Lonhala Magnair Kit uses Glycopyrrolate as the active ingredient. Check out other Drugs and Companies using Glycopyrrolate ingredient

Treatment:

Lonhala Magnair Kit is used for managing chronic obstructive pulmonary disease (COPD) through maintenance treatment of airflow obstruction.

Dosage:

Lonhala Magnair Kit is available in solution form for inhalation use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
25MCG/ML SOLUTION Discontinued INHALATION